Patents by Inventor Ronald Fleming
Ronald Fleming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11280600Abstract: A safety and arming device for a munition is operable to arm and initiate a munition dependent on determining separation from a munition platform, determining detection of free fall of the device for a first time period following separation, initiating a roll manoeuvre of the munition and determining detection of the execution of the roll manoeuvre within a second time period, and generating a munition firing signal, dependent on detection of all of separation, free fall, and the roll manoeuvre.Type: GrantFiled: July 29, 2019Date of Patent: March 22, 2022Assignee: Thales Holdings UK PlcInventors: Laurence Turner, John Morris, Patrick Mallon, Christopher Wilson, Ronald Fleming
-
Publication number: 20210363242Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.Type: ApplicationFiled: January 15, 2019Publication date: November 25, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
-
Patent number: 9192604Abstract: This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene, or a functional fragment thereof, in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected.Type: GrantFiled: June 28, 2012Date of Patent: November 24, 2015Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Kurt R. Auger, Mohammed M. Dar, Ronald A. Fleming
-
Publication number: 20140128434Abstract: This invention relates to a method of treating cancer in a human in need thereof by determining the presence or absence of a detectable amount of a gene product of the Neurofibromin-2 (NF2) gene in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected. This invention also relates to a method of treating cancer in a human in need thereof, comprising determining the presence or absence of a detectable amount of a functional isoform 1 protein of the NF2 gene, or a functional fragment thereof, in a sample from the human, and administering to the human an effective amount of a focal adhesion kinase (FAK) inhibitor, or a pharmaceutically acceptable salt thereof, if no gene product or no isoform 1 gene product is detected.Type: ApplicationFiled: June 28, 2012Publication date: May 8, 2014Inventors: Kurt R. Auger, Mohammed M. Dar, Ronald A. Fleming
-
Patent number: 8138200Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: GrantFiled: December 2, 2009Date of Patent: March 20, 2012Assignees: Wake Forest University, University of North Carolina-Chapel HillInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Publication number: 20100273740Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.Type: ApplicationFiled: November 23, 2009Publication date: October 28, 2010Inventors: Ronald A. FLEMING, Jan V. Hes, Yunsheng Huang, Russ H. Read, Susan L. Morris-Natschke, Khalid S. Ishaq, Louis S. Kucera, Phillip A. Furman
-
Publication number: 20100184718Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: ApplicationFiled: December 2, 2009Publication date: July 22, 2010Inventors: Louis S. KUCERA, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Patent number: 7638528Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: GrantFiled: April 6, 2006Date of Patent: December 29, 2009Assignees: Wake Forest University School of Medicine, The University of North Carolina at Chapel HillInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Patent number: 7309696Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: GrantFiled: December 30, 2003Date of Patent: December 18, 2007Assignees: Wake Forest University, University of North Carolina at Chapel HillInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Publication number: 20070045839Abstract: The invention includes solder materials having low concentrations of alpha particle emitters, and includes methods of purification of materials to reduce a concentration of alpha particle emitters within the materials. The invention includes methods of reducing alpha particle flux in various lead-containing and lead-free materials through purification of the materials. The invention also includes methods of estimating the fractionation of a low concentration of one or more alpha particle emitters during purification of a material.Type: ApplicationFiled: November 2, 2006Publication date: March 1, 2007Inventors: Martin Weiser, Nancy Dean, Brett Clark, Michael Bossio, Ronald Fleming, James Flint
-
Publication number: 20070045842Abstract: The invention includes solder materials having low concentrations of alpha particle emitters, and includes methods of purification of materials to reduce a concentration of alpha particle emitters within the materials. The invention includes methods of reducing alpha particle flux in various lead-containing and lead-free materials through purification of the materials. The invention also includes methods of estimating the fractionation of a low concentration of one or more alpha particle emitters during purification of a material.Type: ApplicationFiled: November 2, 2006Publication date: March 1, 2007Inventors: Martin Weiser, Nancy Dean, Brett Clark, Michael Bossio, Ronald Fleming, James Flint
-
Publication number: 20070045838Abstract: The invention includes solder materials having low concentrations of alpha particle emitters, and includes methods of purification of materials to reduce a concentration of alpha particle emitters within the materials. The invention includes methods of reducing alpha particle flux in various lead-containing and lead-free materials through purification of the materials. The invention also includes methods of estimating the fractionation of a low concentration of one or more alpha particle emitters during purification of a material.Type: ApplicationFiled: November 2, 2006Publication date: March 1, 2007Inventors: Martin Weiser, Nancy Dean, Brett Clark, Michael Bossio, Ronald Fleming, James Flint
-
Publication number: 20060264397Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: ApplicationFiled: April 6, 2006Publication date: November 23, 2006Inventors: Louis Kucera, Ronald Fleming, Khalid Ishaq, Gregory Kucera, Susan Morris-Natschke
-
Publication number: 20060201279Abstract: The invention includes solder materials having low concentrations of alpha particle emitters, and includes methods of purification of materials to reduce a concentration of alpha particle emitters within the materials. The invention includes methods of reducing alpha particle flux in various lead-containing and lead-free materials through purification of the materials. The invention also includes methods of estimating the fractionation of a low concentration of one or more alpha particle emitters during purification of a material.Type: ApplicationFiled: May 5, 2006Publication date: September 14, 2006Inventors: Martin Weiser, Nancy Dean, Brett Clark, Michael Bossio, Ronald Fleming, James Flint
-
Patent number: 7026469Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds, which comprise a phosphocholine moiety covalently conjugated with one or more therapeutic agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt or a prodrug thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus.Type: GrantFiled: April 27, 2001Date of Patent: April 11, 2006Assignees: Wake Forest University School of Medicine, University of North Carolina at ChapelInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Publication number: 20060021427Abstract: Apparatus and methods for airflow testing, especially for air testing of gas turbine components on an airflow test bench. Various embodiments of the present invention include the use of a flow-stabilizing member downstream of the component being tested. Since the flow through or over the component is subsonic, a flow-stabilizing member placed down stream of the component can have an effect on the flow conditions in or around the component being tested. In one embodiment, the flow-stabilizing member provides more consistent results during the testing of the component.Type: ApplicationFiled: March 25, 2003Publication date: February 2, 2006Inventors: Ronald Fleming, August Fleming
-
Publication number: 20050194541Abstract: The invention includes an ionizing radiation detector which includes a chamber within a housing. A receiving member within the chamber has a plurality of spaced holders for receiving samples. The samples are maintained in an array of substantially parallel samples with the samples functioning as electrodes within the chamber. The invention includes a method of counting emissions from samples. An odd number of electrodes are introduced into a detector chamber. Each of the electrodes includes at least one sample to be analyzed. The electrodes are organized into an array of substantially parallel electrodes, each electrode being in electrical communication with a contact surface. The electrode array includes cathodes and anodes where the number of cathodes differs from the number of anodes by one. A voltage is applied across the electrodes and particle emission is detected from the samples based upon ionization of counting gas within the chamber.Type: ApplicationFiled: March 3, 2004Publication date: September 8, 2005Inventors: Brett Clark, Ronald Fleming
-
Publication number: 20050187191Abstract: The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.Type: ApplicationFiled: February 20, 2004Publication date: August 25, 2005Inventors: Louis Kucera, Susan Morris-Natschke, Khalid Ishaq, Ronald Fleming, Jan Hess, Yunsheng Huang, Russ Read, Phillip Furman
-
Publication number: 20050187192Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.Type: ApplicationFiled: February 20, 2004Publication date: August 25, 2005Inventors: Ronald Fleming, Jan Hes, Yunsheng Huang, Russ Read, Susan Morris-Natschke, Khalid Ishaq, Louis Kucera, Phillip Furman
-
Publication number: 20040161398Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: ApplicationFiled: December 30, 2003Publication date: August 19, 2004Applicants: University of North Carolina at Chapel Hill, Wake Forest UniversityInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke